Table 2.

Summary of ongoing trials in the field of non-obstructive coronary artery syndromes.

Trial name	Brief description
MINOCA-BAT (NCT03686696)	The study will randomize 3500 patients with MINOCA to treatment with ACEI or ARB and beta‐blockers or matching placebo. The primary end point of the study is time to mortality of any cause or readmission due to myocardial infarction, ischemic stroke, or heart failure.
WARRIOR (NCT03417388)	This study will evaluate the benefit of intensive statin and ACEI/ARB therapy on major adverse cardiovascular events in symptomatic women with INOCA.
CorCTCA trial (NCT03477890)	The study will clarify the prevalence and clinical significance of INOCA when standard care is based on coronary computed tomography angiography
PRIZE (NCT04097314)	The study will assess the benefit of Zibotentan, an oral endothelin A receptor antagonist, which may help counteract the hypersensitivity to vasoconstriction seen in coronary microvascular dysfunction.

ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CorCTCA = Coronary Microvascular Function and CT Coronary Angiogram; INOCA = ischemia without elevated biomarkers of cardiomyocyte injury in patients with nonobstructive coronary arteries; MINOCA = myocardial infarction with nonobstructive coronary arteries; MINOCA-BAT = Randomized Evaluation of Beta Blocker and ACEI/ARB Treatment in MINOCA patients; PRIZE = Precision Medicine With Zibotentan in Microvascular Angina; WARRIOR = Women’s IschemiA TRial to Reduce Events In Non-ObstRuctive CAD.